Eris Lifesciences Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Amit Bakshi
Chief Executive Officer (CEO)
₹48.8m
Compensación total
| Porcentaje del salario del CEO | 35.9% |
| Permanencia del CEO | 17.3yrs |
| Participación del CEO | 42.9% |
| Permanencia media de la dirección | 7.7yrs |
| Promedio de permanencia en la Junta Directiva | 3.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08Eris Lifesciences Limited's (NSE:ERIS) Risks Elevated At These Prices
Jul 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹49m | ₹17m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹46m | ₹26m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹27m | ₹27m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹3b |
| Jun 30 2020 | n/a | n/a | ₹3b |
| Mar 31 2020 | ₹49m | ₹18m | ₹3b |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹3b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹49m | ₹18m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹49m | ₹11m | ₹3b |
Compensación vs. Mercado: La compensación total de Amit($USD585.56K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD433.80K).
Compensación vs. Ingresos: La compensación de Amit ha sido consistente con los resultados de la empresa en el último año.
CEO
Amit Bakshi (47 yo)
17.3yrs
Permanencia
₹48,776,648
Compensación
Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & MD | no data | ₹48.78m | 42.88% ₹ 52.3b | |
| President | no data | ₹12.31m | sin datos | |
| Chief Financial Officer | 7.7yrs | ₹14.35m | sin datos | |
| Executive Director & COO | 3yrs | ₹44.85m | sin datos | |
| Compliance Officer & Company Secretary | 7.7yrs | sin datos | sin datos | |
| President of Sales & Marketing | no data | ₹11.24m | sin datos | |
| Executive Director | no data | ₹12.40m | 4.37% ₹ 5.3b | |
| Whole Time Director | no data | ₹6.99m | 3.28% ₹ 4.0b | |
| Senior Vice President | no data | ₹12.64m | sin datos | |
| Vice President | no data | ₹13.30m | sin datos | |
| Vice President | no data | ₹10.67m | sin datos | |
| Vice President | no data | ₹13.12m | sin datos |
7.7yrs
Permanencia media
49.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ERIS es experimentado (7.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & MD | 17.3yrs | ₹48.78m | 42.88% ₹ 52.3b | |
| Executive Director & COO | 3.4yrs | ₹44.85m | sin datos | |
| Executive Director | 17.3yrs | ₹12.40m | 4.37% ₹ 5.3b | |
| Whole Time Director | 3.8yrs | ₹6.99m | 3.28% ₹ 4.0b | |
| Independent Director | 6.1yrs | ₹3.98m | sin datos | |
| Independent Director | 1.8yrs | ₹2.82m | sin datos | |
| Independent Director | 3.3yrs | ₹4.53m | sin datos | |
| Independent Director | 3.4yrs | ₹4.20m | sin datos |
3.6yrs
Permanencia media
49yo
Promedio de edad
Junta con experiencia: La junta directiva de ERIS se considera experimentada (3.5 años de antigüedad promedio).